Merck & Co. Deferred Tax Assets decreased by 127.0% to -$315.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 122.4%, from $1.41B to -$315.00M. Over 5 years (FY 2020 to FY 2025), Deferred Tax Assets shows an upward trend with a 39.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase can signal future tax efficiency or the utilization of past losses, while a decrease may indicate the realization of those benefits.
These are assets on the balance sheet that represent future tax savings resulting from temporary differences between the...
Common in large, capital-intensive companies; peers with significant R&D spending often have large deferred tax assets from tax credits.
deferred_tax_assets| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.49B | $1.53B | $2.75B | $3.07B | $2.97B | $2.42B | $1.29B | $1.44B | $996.00M | $1.02B | $1.10B | $922.00M | $876.00M | $864.00M | $2.21B | $1.41B | $1.43B | $1.38B | $1.17B | -$315.00M |
| QoQ Change | — | +2.6% | +80.0% | +11.7% | -3.2% | -18.7% | -46.5% | +11.6% | -30.9% | +2.2% | +7.8% | -16.0% | -5.0% | -1.4% | +156.3% | -36.4% | +1.3% | -3.2% | -15.6% | -127.0% |
| YoY Change | — | — | — | — | +99.7% | +58.3% | -53.0% | -53.0% | -66.5% | -57.9% | -15.1% | -36.1% | -12.0% | -15.1% | +101.8% | +52.8% | +62.9% | +59.8% | -47.3% | -122.4% |